Long‐Term Effects of Highly Active Antiretroviral Therapy on CD4+Cell Evolution among Children and Adolescents Infected with HIV: 5 Years and Counting
Open Access
- 1 June 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (11), 1751-1760
- https://doi.org/10.1086/587900
Abstract
Background. Lower percentages of CD4+ T lymphocytes are associated with adverse clinical outcomes among children and adolescents infected with human immunodeficiency virus (HIV). CD4+ lymphocyte percentage generally increases with receipt of highly active antiretroviral therapy (HAART), but long-term follow-up is required to assess whether these increases in CD4+ cell percentage are maintained and whether they lead to normal CD4+ cell percentages in children with severe immunosuppression. Methods. The study population included 1236 children and adolescents perinatally infected with HIV who were enrolled in a US-based multicenter prospective cohort study (Pediatric AIDS Clinical Trials Group 219/219C) and who were not receiving HAART at study initiation. We estimated the effects of HAART, HAART with protease inhibitors, and HAART with nonnucleoside reverse-transcriptase inhibitors on CD4+ cell percentage, using marginal structural models to account for confounding by severity. Results. Initiation of any type of HAART increased CD4+ cell percentage by 2.34% (95% confidence interval, 1.35%–3.33%) in the first year, relative to noninitiation of HAART. The substantial increases in CD4+ cell percentage observed after the first year of experience with these combination therapies were followed by relatively smaller increases that continued for 5 years after initiation. Although larger increases in CD4+ cell percentage were observed among children with a greater degree of immunosuppression at baseline, the mean CD4+ cell percentage after 5 years of HAART did not reach normal levels. Conclusions. Our study supports the initiation of HAART in children before severe immunosuppression occurs for long-term maintenance of normal CD4+ cell percentages. This beneficial result must be weighed against the evidence of potential adverse events associated with the prolonged use of such therapy.Keywords
This publication has 39 references indexed in Scilit:
- Immunoreconstitution in Children Receiving Highly Active Antiretroviral Therapy Depends on the CD4 Cell Percentage at BaselineThe Journal of Infectious Diseases, 2002
- Impact of Protease Inhibitor-Containing Combination Antiretroviral Therapies on Height and Weight Growth in HIV-Infected ChildrenPEDIATRICS, 2001
- Metabolic Abnormalities in HIV Type 1-Infected Children Treated and Not Treated with Protease InhibitorsAIDS Research and Human Retroviruses, 2001
- Treatment‐Mediated Changes in Human Immunodeficiency Virus (HIV) Type 1 RNA and CD4 Cell Counts as Predictors of Weight Growth Failure, Cognitive Decline, and Survival in HIV‐Infected ChildrenThe Journal of Infectious Diseases, 2000
- Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377AIDS Research and Human Retroviruses, 2000
- Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1999
- Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected childrenAIDS, 1999
- A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV InfectionPEDIATRICS, 1998
- A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus InfectionPEDIATRICS, 1998
- Age- and Time-related Changes in Extracellular Viral Load in Children Vertically Infected by Human Immunodeficiency VirusThe Pediatric Infectious Disease Journal, 1996